Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.660
-0.040 (-2.35%)
At close: Jun 20, 2025, 4:00 PM
1.690
+0.030 (1.81%)
After-hours: Jun 20, 2025, 5:23 PM EDT
Inhibikase Therapeutics Employees
As of December 31, 2024, Inhibikase Therapeutics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees increased by 7 or 77.78% compared to the previous year.
Employees
16
Change (1Y)
7
Growth (1Y)
77.78%
Revenue / Employee
n/a
Profits / Employee
-$2,284,312
Market Cap
123.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 7 | 77.78% |
| Dec 31, 2023 | 9 | 2 | 28.57% |
| Dec 31, 2022 | 7 | 0 | - |
| Dec 31, 2021 | 7 | 4 | 133.33% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IKT News
- 5 weeks ago - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 4 months ago - Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewsWire
- 4 months ago - Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - Reuters
- 7 months ago - Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
- 7 months ago - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewsWire